Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Product Pipeline
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
ADAPTING
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology, Inc.
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotech Surges, Defying Yellen
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
PUMA_BIOTECHNOLOGY
printmgr file
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Workable Strategic Report on Breast Cancer Therapeutics Drugs
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotech punts near $300 million on Takeda discard
